ZVSA Stock Overview

A clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. More details

ZVSA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap ($2M)

Shareholders have been substantially diluted in the past year

Earnings have declined by 47.4% per year over past 5 years

+ 1 more risk

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

ZyVersa Therapeutics, Inc. Competitors

Protagenic Therapeutics

NasdaqCM:PTIX

US$1.9m

Pasithea Therapeutics

NasdaqCM:KTTA

US$1.6m

Palisade Bio

NasdaqCM:PALI

US$2.0m

Vincerx Pharma

NasdaqCM:VINC

US$1.5m

Price History & Performance

Summary of share price highs, lows and changes for ZyVersa Therapeutics
Historical stock prices
Current Share Price	US$0.74
52 Week High	US$8.40
52 Week Low	US$0.70
Beta	0.47
1 Month Change	-38.93%
3 Month Change	-36.32%
1 Year Change	-90.87%
3 Year Change	-99.98%
5 Year Change	n/a
Change since IPO	-99.98%

Recent updates

Shareholder Returns

	ZVSA	US Biotechs	US Market
7D	-5.7%	-2.4%	-0.2%
1Y	-90.9%	-6.8%	8.1%

Return vs Industry: ZVSA underperformed the US Biotechs industry which returned -6.8% over the past year.

Return vs Market: ZVSA underperformed the US Market which returned 7.9% over the past year.

Price Volatility

Is ZVSA's price volatile compared to industry and market?
ZVSA volatility
ZVSA Average Weekly Movement	14.2%
Biotechs Industry Average Movement	10.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	17.0%
10% least volatile stocks in US Market	3.2%

Stable Share Price: ZVSA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ZVSA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2014	7	Steve Glover	www.zyversa.com

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson’s and Huntington’s disease, atherosclerosis, Alzheimer’s disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

ZyVersa Therapeutics, Inc. Fundamentals Summary

How do ZyVersa Therapeutics's earnings and revenue compare to its market cap?
ZVSA fundamental statistics
Market cap	US$1.75m
Earnings (TTM)	-US$21.33m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Is ZVSA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ZVSA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$21.33m
Earnings	-US$21.33m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-9.10
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ZVSA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/23 04:09
End of Day Share Price	2025/03/21 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ZyVersa Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Robert LeBoyer	NOBLE Capital Markets, Inc.

ZVSA Stock Overview

Risk Analysis

ZyVersa Therapeutics, Inc. Competitors

NasdaqCM:PTIX

US$1.9m

NasdaqCM:KTTA

US$1.6m

NasdaqCM:PALI

US$2.0m

NasdaqCM:VINC

US$1.5m

Price History & Performance

Recent News & Updates

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study

ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model

ZyVersa Therapeutics, Inc. announced that it expects to receive $2.000002 million in funding

ZyVersa Therapeutics, Inc. Highlights Newly Published Data Demonstrating Cardioprotective Effects and Improvements in Metabolic Parameters

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100

ZyVersa Therapeutics, Inc. Forms New Scientific Advisory Board

Recent updates

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study

ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model

ZyVersa Therapeutics, Inc. announced that it expects to receive $2.000002 million in funding

ZyVersa Therapeutics, Inc. Highlights Newly Published Data Demonstrating Cardioprotective Effects and Improvements in Metabolic Parameters

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100

ZyVersa Therapeutics, Inc. Forms New Scientific Advisory Board

ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.397396 million.

ZyVersa Therapeutics, Inc., Annual General Meeting, Oct 29, 2024

ZyVersa Therapeutics, Inc. Announces Publish Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

ZyVersa Therapeutics, Inc. Announces IRB Approval of Phase 2A Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease

ZyVersa Therapeutics Receives Letter of Reprimand from Nasdaq in Accordance with Nasdaq’s Listing Rule 5810(c)(4)

ZyVersa Therapeutics Receives Approval from Nasdaq to Transfer the Listing of Common Stock from the Nasdaq Global Market to the Nasdaq Capital Market

ZyVersa Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.99964 million.

Nasdaq Issues A Letter to ZyVersa Therapeutics, Inc. Regarding Listing Rule 5810(c)(3)(A)(iii)

Nasdaq Issues A Letter to ZyVersa Therapeutics, Inc. Regarding Listing Rule 5810(c)(3)(A)(iii)

High number of new and inexperienced directors

ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering.

ZyVersa Therapeutics, Inc. has filed a Follow-on Equity Offering.

ZyVersa Therapeutics, Inc. Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating that Inflammasome ASC Inhibitor IC 100 Attenuates Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection

ZyVersa Therapeutics, Inc. Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100's Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease

ZyVersa Therapeutics, Inc. Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues

Zyversa Therapeutics Announces Research Published in the Journal of Clinical Investigation Reinforcing Ic 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues

Zyversa Therapeutics, Inc. Announces Research Published in Frontiers in Immunology Reinforcing Ic 100'S Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases

ZyVersa Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq

ZyVersa Therapeutics, Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023

ZyVersa Therapeutics, Inc., Annual General Meeting, Oct 31, 2023

ZyVersa Therapeutics, Inc. announced delayed 10-Q filing

ZyVersa Therapeutics, Inc. Announces European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator™? VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease

ZyVersa Therapeutics, Inc. Announces Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arterial Disease

ZyVersa Therapeutics Receives Non-Compliance Letter Form Nasdaq

European Patent Office to Grant Zyversa Therapeutics' Patent Application for Cholesterol Transport Mediator™? Var 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease

ZyVersa Therapeutics, Inc. Announces Changes to Board of Directors

ZyVersa Therapeutics, Inc. Appoints Dr. Pablo Guzman as Chief Medical Officer and Senior Vice President of Medical Affairs

Less than half of directors are independent

ZyVersa Therapeutics, Inc. Announces Executive Changes

ZyVersa Therapeutics, Inc. Adds Two Esteemed Leaders to Its Renal Scientific Advisory Board

High number of new directors

No independent directors

ZyVersa Therapeutics, Inc. completed the acquisition of Larkspur Health Acquisition Corp. (NasdaqGM:LSPR) from Larkspur Health LLC, A.G.P. / Alliance Global Partners Corp. and others in a reverse merger transaction.